Given that the super-enhancer landscape undergoes significant reprogramming in cancer, exploring differential enhancers active in tumors can shed light on how epigenetic events may contribute to the dysregulation of FST in HNSCC. The gene discussed is FST; the disease is head and neck squamous cell carcinoma.